Rana McKay, MD introduces a metastatic castration-resistant prostate cancer (mCRPC) patient case featuring a 72-year-old man with a history of metastatic castration-resistant prostate cancer.
Rana R. McKay, MD
Rana R. McKay, MD, is a board-certified medical oncologist who specializes in treating people with urogenital cancers at UC San Diego Health.
Articles by Rana R. McKay, MD
A panel of expert genitourinary oncologists give an overview of renal cell carcinoma and present the case of a 61-year-old man with metastatic clear cell RCC.
Rana McKay, MD closes by offering actionable advice for community oncologists and considers the potential clinical implications of these and other emerging data.
Discussion centered around the unmet needs that the COSMIC-313 trial aims to address, as well as information about included patient populations, study design, and recent conference data.
Dr McKay reviews key trial data from the CheckMate 9ER trial including eligible patient populations, study design, and safety/efficacy data.
Rana McKay, MD presents an overview of metastatic/stage IV RCC, touching on incidence, the typical RCC patient she sees in her practice, and available first-line treatments for metastatic clear cell RCC.
Rana McKay, MD, shares advice for community oncologists treating patients with advanced renal cell carcinoma.
Dr Rana McKay discusses the rationale for using cabozantinib with nivolumab and ipilimumab in the COSMIC 313 trial and reviews the adverse events seen with this combination in the COSMIC 313 trial.
Dr Rana McKay reviews key efficacy data from the COSMIC 313 trial and discusses factors that are considered when choosing between IO-TKI or IO-IO combinations.
Dr Rana McKay discusses the efficacy and qualify-of-life data from the 5-year follow-up of the CheckMate 214 trial investigating nivolumab plus ipilimumab in frontline advanced renal cell carcinoma treatment.
Rana McKay, MD, presents the case of a 73-year-old man with advanced renal cell carcinoma, shares her initial impression, and reviews which factors contribute to a patient’s risk status.
Rana R. McKay, MD, discusses KEYNOTE-564 and the future of adjuvant immunotherapy in renal cell carcinoma.
Rana R. McKay, MD, discusses the combination of nivolumab and cabozantinib versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma.
Rana R. McKay, MD, discusses the phase 2 OMNIVORE trial of nivolumab and ipilimumab in patients with advanced renal cell carcinoma.
Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses advances in the treatment of metastatic renal cell carcinoma (RCC).
Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, discusses the mechanism of action of dutasteride and its role in a phase II prostate cancer trial.
Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, discusses treatment options for biochemical relapse after definitive local therapy for prostate cancer.
Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, discusses a trial that analyzed overall survival in patients with metastatic renal cell carcinoma who used angiotensin system inhibitors.